{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:23:59Z","timestamp":1794201839436,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA263229"],"award-info":[{"award-number":["R21CA263229"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA082103"],"award-info":[{"award-number":["P30 CA082103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA082103"],"award-info":[{"award-number":["P30CA082103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006111","name":"Michelson Prize and Grants","doi-asserted-by":"publisher","award":["Michelson Prize"],"award-info":[{"award-number":["Michelson Prize"]}],"id":[{"id":"10.13039\/100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM087221"],"award-info":[{"award-number":["R01GM087221"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM074830"],"award-info":[{"award-number":["R01GM074830"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM145249"],"award-info":[{"award-number":["R35GM145249"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM130144"],"award-info":[{"award-number":["R01GM130144"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["S10OD026936"],"award-info":[{"award-number":["S10OD026936"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1920268"],"award-info":[{"award-number":["1920268"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOPS-136944"],"award-info":[{"award-number":["MOPS-136944"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface markers. Here we explore the hypothesis that tumor cells express cancer-specific surface protein conformations that are invisible to standard target discovery pipelines evaluating gene or protein expression, and these conformations can be identified and immunotherapeutically targeted. We term this strategy integrating cross-linking mass spectrometry with glycoprotein surface capture \u2018structural surfaceomics\u2019. As a proof of principle, we apply this technology to acute myeloid leukemia (AML), a hematologic malignancy with dismal outcomes and no known optimal immunotherapy target. We identify the activated conformation of integrin \u03b2<jats:sub>2<\/jats:sub> as a structurally defined, widely expressed AML-specific target. We develop and characterize recombinant antibodies to this protein conformation and show that chimeric antigen receptor T cells eliminate AML cells and patient-derived xenografts without notable toxicity toward normal hematopoietic cells. Our findings validate an AML conformation-specific target antigen and demonstrate a tool kit for applying these strategies more broadly.<\/jats:p>","DOI":"10.1038\/s43018-023-00652-6","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T17:02:06Z","timestamp":1698685326000},"page":"1592-1609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target"],"prefix":"10.1038","volume":"4","author":[{"given":"Kamal","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianina","family":"Wicaksono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarrett J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hoopmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-3261","authenticated-orcid":false,"given":"Adila","family":"Izgutdina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-4822","authenticated-orcid":false,"given":"Bonell Pati\u00f1o","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryna","family":"Gorelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2419-4391","authenticated-orcid":false,"given":"Christian H.","family":"Ihling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-5368","authenticated-orcid":false,"given":"Matthew A.","family":"Nix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akul","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwita","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynn","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio Camara","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Salangsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Phojanakong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gavallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Leavitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-1190","authenticated-orcid":false,"given":"Justin","family":"Eyquem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1521-4899","authenticated-orcid":false,"given":"Andrea","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-0833","authenticated-orcid":false,"given":"Benjamin J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-4623","authenticated-orcid":false,"given":"Elliot","family":"Stieglitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-9447","authenticated-orcid":false,"given":"Robert L.","family":"Moritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-5918","authenticated-orcid":false,"given":"Sachdev S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-4687","authenticated-orcid":false,"given":"Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"652_CR1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"652_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1101\/gr.124347.111","volume":"22","author":"JD Brooks","year":"2012","unstructured":"Brooks, J. D. Translational genomics: the challenge of developing cancer biomarkers. Genome Res. 22, 183\u2013187 (2012).","journal-title":"Genome Res."},{"key":"652_CR3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody\u2013drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"652_CR4","doi-asserted-by":"crossref","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","DOI":"10.1182\/blood-2016-04-703751"},{"key":"652_CR5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen, N. et al. The activated conformation of integrin \u03b27 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat. Med. 23, 1436\u20131443 (2017).","journal-title":"Nat. Med."},{"key":"652_CR6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nprot.2013.168","volume":"9","author":"A Leitner","year":"2014","unstructured":"Leitner, A., Walzthoeni, T. & Aebersold, R. Lysine-specific chemical cross-linking of protein complexes and identification of cross-linking sites using LC\u2013MS\/MS and the xQuest\/xProphet software pipeline. Nat. Protoc. 9, 120\u2013137 (2014).","journal-title":"Nat. Protoc."},{"key":"652_CR7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1021\/acs.analchem.7b04431","volume":"90","author":"C Yu","year":"2018","unstructured":"Yu, C. & Huang, L. Cross-linking mass spectrometry (XL\u2013MS): an emerging technology for interactomics and structural biology. Anal. Chem. 90, 144\u2013165 (2018).","journal-title":"Anal. Chem."},{"key":"652_CR8","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1021\/acs.chemrev.1c00786","volume":"122","author":"L Piersimoni","year":"2022","unstructured":"Piersimoni, L., Kastritis, P. L., Arlt, C. & Sinz, A. Cross-linking mass spectrometry for investigating protein conformations and protein\u2013protein interactions\u2014a method for all seasons. Chem. Rev. 122, 7500\u20137531 (2022).","journal-title":"Chem. Rev."},{"key":"652_CR9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1021\/acscentsci.9b00416","volume":"5","author":"B Steigenberger","year":"2019","unstructured":"Steigenberger, B., Pieters, R. J., Heck, A. J. R. & Scheltema, R. A. PhoX: an IMAC-enrichable cross-linking reagent. ACS Cent. Sci. 5, 1514\u20131522 (2019).","journal-title":"ACS Cent. Sci."},{"key":"652_CR10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nbt.1532","volume":"27","author":"B Wollscheid","year":"2009","unstructured":"Wollscheid, B. et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat. Biotechnol. 27, 378\u2013386 (2009).","journal-title":"Nat. Biotechnol."},{"key":"652_CR11","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","volume":"11","author":"MA Nix","year":"2021","unstructured":"Nix, M. A. et al. Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL. Cancer Discov. 11, 2032\u20132049 (2021).","journal-title":"Cancer Discov."},{"key":"652_CR12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519 (2017).","journal-title":"Cancer Cell"},{"key":"652_CR13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 11, 41 (2021).","journal-title":"Blood Cancer J."},{"key":"652_CR14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana, S. & Gill, S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front. Oncol. 10, 697 (2020).","journal-title":"Front. Oncol."},{"key":"652_CR15","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.3390\/cancers13246157","volume":"13","author":"M Maucher","year":"2021","unstructured":"Maucher, M. et al. Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia. Cancers 13, 6157 (2021).","journal-title":"Cancers"},{"key":"652_CR16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian, S. S. et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29, 1637\u20131647 (2015).","journal-title":"Leukemia"},{"key":"652_CR17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V122.21.143.143","volume":"122","author":"S Gill","year":"2013","unstructured":"Gill, S. et al. Anti-CD123 chimeric antigen receptor T cells (CART-123) provide a novel myeloablative conditioning regimen that eradicates human acute myeloid leukemia in preclinical models. Blood 122, 143 (2013).","journal-title":"Blood"},{"key":"652_CR18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/10428190310001609942","volume":"45","author":"H Quentmeier","year":"2004","unstructured":"Quentmeier, H. et al. Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. Leuk. Lymphoma 45, 567\u2013574 (2004).","journal-title":"Leuk. Lymphoma"},{"key":"652_CR19","first-page":"M110.002212","volume":"10","author":"A Kao","year":"2011","unstructured":"Kao, A. et al. Development of a novel cross-linking strategy for fast and accurate identification of cross-linked peptides of protein complexes. Mol. Cell. Proteomics 10, M110.002212 (2011).","journal-title":"Mol. Cell. Proteomics"},{"key":"652_CR20","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nmeth.3603","volume":"12","author":"F Liu","year":"2015","unstructured":"Liu, F., Rijkers, D. T. S., Post, H. & Heck, A. J. R. Proteome-wide profiling of protein assemblies by cross-linking mass spectrometry. Nat. Methods 12, 1179\u20131184 (2015).","journal-title":"Nat. Methods"},{"key":"652_CR21","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41596-018-0074-x","volume":"13","author":"O Klykov","year":"2018","unstructured":"Klykov, O. et al. Efficient and robust proteome-wide approaches for cross-linking mass spectrometry. Nat. Protoc. 13, 2964\u20132990 (2018).","journal-title":"Nat. Protoc."},{"key":"652_CR22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/prca.201400164","volume":"9","author":"EW Deutsch","year":"2015","unstructured":"Deutsch, E. W. et al. Trans-Proteomic Pipeline, a standardized data processing pipeline for large-scale reproducible proteomics informatics. Proteomics Clin. Appl. 9, 745\u2013754 (2015).","journal-title":"Proteomics Clin. Appl."},{"key":"652_CR23","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/acs.analchem.1c04485","volume":"94","author":"F Jiao","year":"2022","unstructured":"Jiao, F. et al. Two-dimensional fractionation method for proteome-wide cross-linking mass spectrometry analysis. Anal. Chem. 94, 4236\u20134242 (2022).","journal-title":"Anal. Chem."},{"key":"652_CR24","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","volume":"13","author":"ID Ferguson","year":"2022","unstructured":"Ferguson, I. D. et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat. Commun. 13, 4121 (2022).","journal-title":"Nat. Commun."},{"key":"652_CR25","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1073\/pnas.1601379113","volume":"113","author":"M Sen","year":"2016","unstructured":"Sen, M. & Springer, T. A. Leukocyte integrin \u03b1l\u03b22 headpiece structures: the \u03b1i domain, the pocket for the internal ligand, and concerted movements of its loops. Proc. Natl Acad. Sci. USA 113, 2940\u20132945 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"652_CR26","doi-asserted-by":"crossref","first-page":"14727","DOI":"10.1073\/pnas.1008663107","volume":"107","author":"X Chen","year":"2010","unstructured":"Chen, X. et al. Requirement of open headpiece conformation for activation of leukocyte integrin \u03b1X\u03b22. Proc. Natl Acad. Sci. USA 107, 14727\u201314732 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"652_CR27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fimmu.2019.00254","volume":"10","author":"SC Fagerholm","year":"2019","unstructured":"Fagerholm, S. C., Guenther, C., Asens, M. L., Savinko, T. & Uotila, L. M. \u03b22-integrins and interacting proteins in leukocyte trafficking, immune suppression, and immunodeficiency disease. Front. Immunol. 10, 254 (2019).","journal-title":"Front. Immunol."},{"key":"652_CR28","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3389\/fimmu.2017.01866","volume":"8","author":"L Schittenhelm","year":"2017","unstructured":"Schittenhelm, L., Hilkens, C. M. & Morrison, V. L. \u03b22 integrins as regulators of dendritic cell, monocyte, and macrophage function. Front. Immunol. 8, 1866 (2017).","journal-title":"Front. Immunol."},{"key":"652_CR29","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.4049\/jimmunol.1203179","volume":"190","author":"J Herter","year":"2020","unstructured":"Herter, J. & Zarbock, A. Integrin regulation during leukocyte recruitment. J. Immunol. 190, 4451\u20134457 (2020).","journal-title":"J. Immunol."},{"key":"652_CR30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley, K., Laudanna, C., Cybulsky, M. I. & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678\u2013689 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"652_CR31","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.4049\/jimmunol.180.10.6439","volume":"180","author":"B Petri","year":"2008","unstructured":"Petri, B., Phillipson, M. & Kubes, P. The physiology of leukocyte recruitment: an in vivo perspective. J. Immunol. 180, 6439\u20136446 (2008).","journal-title":"J. Immunol."},{"key":"652_CR32","doi-asserted-by":"crossref","unstructured":"Phillipson, M. & Kubes, P. The neutrophil in vascular inflammation. Nat. Med. 17, 1381\u20131390 (2011).","DOI":"10.1038\/nm.2514"},{"key":"652_CR33","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1182\/blood-2012-09-457887","volume":"121","author":"T Oellerich","year":"2017","unstructured":"Oellerich, T., Oellerich, M. F., Engelke, M. & Silvia, M. \u03b22 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk\/STAT signaling axis. Blood 121, 3889\u20133900 (2017).","journal-title":"Blood"},{"key":"652_CR34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1083\/jcb.116.1.219","volume":"116","author":"I Dransfield","year":"1992","unstructured":"Dransfield, I., Caba\u00f1as, C., Craig, A. & Hogg, N. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J. Cell Biol. 116, 219\u2013226 (1992).","journal-title":"J. Cell Biol."},{"key":"652_CR35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend, E. C. et al. The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 29, 574\u2013586 (2016).","journal-title":"Cancer Cell"},{"key":"652_CR36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"652_CR37","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"652_CR38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2017","unstructured":"Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24, 103\u2013112 (2017).","journal-title":"Nat. Med."},{"key":"652_CR39","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"652_CR40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0008-8749(85)90006-1","volume":"92","author":"N Hogg","year":"1985","unstructured":"Hogg, N. & Selvendran, Y. An anti-human monocyte\/macrophage monoclonal antibody, reacting most strongly with macrophages in lymphoid tissue. Cell. Immunol. 92, 247\u2013253 (1985).","journal-title":"Cell. Immunol."},{"key":"652_CR41","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.0605716103","volume":"103","author":"M Shimaoka","year":"2006","unstructured":"Shimaoka, M. et al. AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc. Natl Acad. Sci. USA 103, 13991\u201313996 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"652_CR42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jmb.2012.11.037","volume":"425","author":"H Persson","year":"2013","unstructured":"Persson, H. et al. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J. Mol. Biol. 425, 803\u2013811 (2013).","journal-title":"J. Mol. Biol."},{"key":"652_CR43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2011-04-292128","volume":"119","author":"F Ye","year":"2012","unstructured":"Ye, F., Kim, C. & Ginsberg, M. H. Reconstruction of integrin activation. Blood 119, 26\u201333 (2012).","journal-title":"Blood"},{"key":"652_CR44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto, J. et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat. Med. 28, 345\u2013352 (2022).","journal-title":"Nat. Med."},{"key":"652_CR45","doi-asserted-by":"crossref","first-page":"820058","DOI":"10.3389\/fimmu.2022.820058","volume":"13","author":"M Blanter","year":"2022","unstructured":"Blanter, M. et al. Method matters: effect of purification technology on neutrophil phenotype and function. Front. Immunol. 13, 820058 (2022).","journal-title":"Front. Immunol."},{"key":"652_CR46","doi-asserted-by":"crossref","unstructured":"Allen, T. M. et al. Humanized immune system mouse models: progress, challenges and opportunities. Nat. Immunol. 20, 770\u2013774 (2019).","DOI":"10.1038\/s41590-019-0416-z"},{"key":"652_CR47","doi-asserted-by":"crossref","first-page":"15142","DOI":"10.1073\/pnas.0806486105","volume":"105","author":"PG DeCaen","year":"2008","unstructured":"DeCaen, P. G., Yarov-Yarovoy, V., Zhao, Y., Scheuer, T. & Catterall, W. A. Disulfide locking a sodium channel voltage sensor reveals ion pair formation during activation. Proc. Natl Acad. Sci. USA 105, 15142\u201315147 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"652_CR48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma, H., Padmanabhan, I. S., Parmar, S. & Gong, Y. Targeting CLL-1 for acute myeloid leukemia therapy. J. Hematol. Oncol. 12, 41 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"652_CR49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","volume":"36","author":"S Li","year":"2016","unstructured":"Li, S., Mason, C. & Melnick, A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr. Opin. Genet. Dev. 36, 100\u2013106 (2016).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"652_CR50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nmeth.4256","volume":"14","author":"AT Kong","year":"2017","unstructured":"Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat. Methods 14, 513\u2013520 (2017).","journal-title":"Nat. Methods"},{"key":"652_CR51","doi-asserted-by":"crossref","first-page":"R110.000133","DOI":"10.1074\/mcp.R110.000133","volume":"10","author":"L Martens","year":"2011","unstructured":"Martens, L. et al. mzML\u2014a community standard for mass spectrometry data. Mol. Cell. Proteomics 10, R110.000133 (2011).","journal-title":"Mol. Cell. Proteomics"},{"key":"652_CR52","doi-asserted-by":"crossref","first-page":"2005.0017","DOI":"10.1038\/msb4100024","volume":"1","author":"A Keller","year":"2005","unstructured":"Keller, A., Eng, J., Zhang, N., Li, X. J. & Aebersold, R. A uniform proteomics MS\/MS analysis platform utilizing open XML file formats. Mol. Syst. Biol. 1, 2005.0017 (2005).","journal-title":"Mol. Syst. Biol."},{"key":"652_CR53","doi-asserted-by":"crossref","first-page":"11442","DOI":"10.1021\/acs.analchem.1c01317","volume":"93","author":"CH Ihling","year":"2021","unstructured":"Ihling, C. H., Piersimoni, L., Kipping, M. & Sinz, A. Cross-linking\/mass spectrometry combined with ion mobility on a timsTOF Pro instrument for structural proteomics. Anal. Chem. 93, 11442\u201311450 (2021).","journal-title":"Anal. Chem."},{"key":"652_CR54","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nbt.2377","volume":"30","author":"MC Chambers","year":"2012","unstructured":"Chambers, M. C. et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30, 918\u2013920 (2012).","journal-title":"Nat. Biotechnol."},{"key":"652_CR55","volume":"10","author":"ZL Chen","year":"2019","unstructured":"Chen, Z. L. et al. A high-speed search engine pLink 2 with systematic evaluation for proteome-scale identification of cross-linked peptides. Nat. Commun. 10, 3404 (2019).","journal-title":"Nat. Commun."},{"key":"652_CR56","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944\u2013949 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"652_CR57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR\u2013Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"652_CR58","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242\u2013W245 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00652-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00652-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:30:51Z","timestamp":1700641851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00652-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00652-6","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.M., J.J.A., S.S.S. and A.P.W. have filed a patent related to the antibody sequences described herein. A.P.W. has received research funding from Genentech. C.S. has received research funding from Revolution Medicines, Abbvie and Erasca and has served on advisory boards for Genentech, Abbvie and Astellas. C.M.R. has equity in Allovir and Marker Therapeutics, has received research support from Tessa Therapeutics and is on the Scientific Advisory Board of Tessa Therapeutics and Marker. The spouse of C.M.R. has served on advisory boards for Walking Fish Therapeutics, CellGenix, Marker Therapeutics, Tessa Therapeutics, Abintus, Allogene, Bellicum Pharmaceuticals, Bluebird Bio, Athenex, Memgen, Turnstone Biologics, Coya Therapeutics, TScan Therapeutics, Onkimmune, Poseida Therapeutics and Allovir. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}